Literature DB >> 30228579

Chronic Lymphocytic Leukemia and the Side Effects of Therapy: 2017 Review.

Asim Ahmad1, Clint Daniel Kingsley2.   

Abstract

In recent years, the choice of therapies for symptomatic Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) have grown exponentially, with no single agreed upon standard first-line therapy. The choice of therapy is often dictated by goals of care, patient characteristics and tumor genetic abnormalities. The goal of this article is to familiarize the primary care provider with some of the most commonly used therapeutic modalities with attention to the side effect profile of these regimens.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 30228579      PMCID: PMC6140236     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  9 in total

Review 1.  How I treat CLL up front.

Authors:  John G Gribben
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

2.  A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.

Authors:  Craig Reynolds; Nicholas Di Bella; Roger M Lyons; William Hyman; Donald A Richards; Gerald J Robbins; Mark Vellek; Kristi A Boehm; Feng Zhan; Lina Asmar
Journal:  Invest New Drugs       Date:  2011-09-16       Impact factor: 3.850

3.  Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-05-19       Impact factor: 13.506

4.  The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.

Authors:  S Gill; D Carney; D Ritchie; M Wolf; D Westerman; H M Prince; H Januszewicz; J F Seymour
Journal:  Ann Oncol       Date:  2009-07-22       Impact factor: 32.976

5.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

6.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

7.  Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.

Authors:  Paolo Strati; William Wierda; Jan Burger; Alessandra Ferrajoli; Constantine Tam; Susan Lerner; Michael J Keating; Susan O'Brien
Journal:  Cancer       Date:  2013-08-13       Impact factor: 6.860

8.  First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

Authors:  Barbara Eichhorst; Anna-Maria Fink; Jasmin Bahlo; Raymonde Busch; Gabor Kovacs; Christian Maurer; Elisabeth Lange; Hubert Köppler; Michael Kiehl; Martin Sökler; Rudolf Schlag; Ursula Vehling-Kaiser; Georg Köchling; Christoph Plöger; Michael Gregor; Torben Plesner; Marek Trneny; Kirsten Fischer; Harmut Döhner; Michael Kneba; Clemens-Martin Wendtner; Wolfram Klapper; Karl-Anton Kreuzer; Stephan Stilgenbauer; Sebastian Böttcher; Michael Hallek
Journal:  Lancet Oncol       Date:  2016-05-20       Impact factor: 41.316

9.  Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.

Authors:  A Smith; D Howell; R Patmore; A Jack; E Roman
Journal:  Br J Cancer       Date:  2011-11-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.